A recent randomized, open-label trial comparing rivaroxaban to warfarin in APS - Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) - with triple aPL positivity (~21% of patients had SLE-APS) was prematurely terminated due to an excess of thromboembolic events in the rivaroxaban arm [9]. This evidence concerns the gene FASLG and systemic lupus erythematosus.